Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

ASCO 2018 | Elderly cancer patients who report symptoms have greater survival

Raúl Córdoba • 14 Jun 2018
ASCO 2018
Lymphoma

Speaking from the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL, Raúl Córdoba, MD, PhD, MS, of the Fundacion Jimenez Diaz University Hospital, Madrid, Spain, describes an innovative trial of elderly patients with malignancies that investigated the effect of patients reporting their symptoms and adverse events while receiving chemotherapy.

More from Raúl Córdoba

The pharmacometrics of odronextamab in R/R FL & DLBCL based on the ELM-1 & 2 studies 1:30
The pharmacometrics of odronextamab in R/R FL & DLBCL based on the ELM-1 & 2 studies
Raúl Córdoba • 15 Jun 2024
Epcoritamab combined with GemOx in B-NHL: updated results from EPCORE NHL-2 1:11
Epcoritamab combined with GemOx in B-NHL: updated results from EPCORE NHL-2
Raúl Córdoba • 15 Jun 2024
Preventing and monitoring cardiotoxicities associated with treatment for hematologic malignancies 1:27
Preventing and monitoring cardiotoxicities associated with treatment for hematologic malignancies
Raúl Córdoba • 15 Jun 2024
Comprehensive geriatric assessments can aid in selecting treatment for elderly patients with CLL 2:03
Comprehensive geriatric assessments can aid in selecting treatment for elderly patients with CLL
Raúl Córdoba • 7 Oct 2023

Related Videos

A retrospective study of Pola-R-CHP versus R+DA-EPOCH in high-risk DLBCL 1:58
A retrospective study of Pola-R-CHP versus R+DA-EPOCH in high-risk DLBCL
Rahul Thakur • 8 Dec 2025
Glofitamab-GemOx versus R-GemOx in transplant-ineligible R/R DLBCL: subgroup analysis of STARGLO 2:24
Glofitamab-GemOx versus R-GemOx in transplant-ineligible R/R DLBCL: subgroup analysis of STARGLO
Haifaa Abdulhaq • 8 Dec 2025
Epcoritamab + R2 or epcoritamab maintenance in 1L FL: 3-year outcomes from EPCORE NHL-2 arms 6 & 7 2:53
Epcoritamab + R2 or epcoritamab maintenance in 1L FL: 3-year outcomes from EPCORE NHL-2 arms 6 & 7
Lori Leslie • 7 Dec 2025
Extended follow-up from a Phase I/II study of golcadomide ± rituximab in patients with R/R DLBCL 1:35
Extended follow-up from a Phase I/II study of golcadomide ± rituximab in patients with R/R DLBCL
Marc Hoffman • 7 Dec 2025
The content of VJHemOnc is intended for healthcare professionals